Cambridge biotech Sarepta wins fast-track approval for the first muscular dystrophy gene therapy

The FDA limited the approval of Sarepta Therapeutics’ treatment to patients ages 4 to 5 years old who still have the ability to walk.

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,United States ,Massachusetts ,Americans ,Debra Miller ,Ruby Wallau ,Peter Marks ,Anthony Amato ,Michael Abrams ,G Caleb Alexander ,Ted Kaye ,Diana Zuckerman ,Doug Ingram ,Muscular Dystrophy Association ,Public Citizen Health Research Group ,Drug Administration ,Health Research ,National Center ,Johns Hopkins Bloomberg School Of Public Health ,Public Citizen ,Mike Singer ,Biologics Evaluation ,Muscular Dystrophy ,Johns Hopkins Bloomberg School ,Silver Spring ,Stoke Therapeutics , ,